An interventional study of Lungpacer Diaphragm Pacing Therapy in Ventilator Induced Diaphragm Dysfunction (VIDD), sponsored by Lungpacer Medical Inc.. Terminated at 33 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Lungpacer Medical Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Ventilator-Induced Lung Injury with a site in United States — 4 open to participants now, 6 under way, none of them phase 3. Ventilator-Induced Lung Injury · United States.
Among the 23 studies in Ventilator-Induced Lung Injury with a site in United States, this one is the 3rd largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2019, is one of 14 with no phase, and was the 10th registered.
122 studies on the registry are indexed under Ventilator-Induced Lung Injury; 40 are open to participants now.
Browse Ventilator-Induced Lung Injury studies →4 of the 23 studies in Ventilator-Induced Lung Injury with a site in United States are open now. Recruiting first, the newest first:
Technische Universität Dresden · Sites in United States, Germany, Serbia and 2 more countries
Ages 18+
Children's Hospital Los Angeles · Sites in United States, Canada, Italy
Ages 1 mo–18 yrs
University of California, San Diego · Sites in United States
Ages 18+
University of Virginia · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 22 Ventilator-Induced Lung Injury studies recruiting now, 15 (68%) set no upper age limit and 5 (23%) stop at 75 or younger; 5 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 2 · Phase 4 1
First in 2008; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 223 is above the median of 40 across 76 interventional studies indexed under Ventilator-Induced Lung Injury.
Median enrollment 31 across the 18 interventional studies, 176 across the 5 observational. Of the 13 that completed or were terminated, 7 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 23 have an industry lead sponsor. The 10 most frequent:
Lungpacer Medical Inc. is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Lungpacer Medical Inc. has 3 studies filed under Ventilator-Induced Lung Injury — fewer than ten, so there is no comparison to draw.
2 of the studies in Ventilator-Induced Lung Injury with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04068012Children's Hospital Los AngelesClinical Decision Support Tool in PARDS Pilot Study | 2027-07 |
| NCT05977153The University of Texas Medical Branch, GalvestonCT for Personalized Mechanical Ventilation | 2027-08-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 23 studies in Ventilator-Induced Lung Injury with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical investigation is an open-label, multi-center, randomized clinical trial (RCT) to demonstrate the safety and effective performance of the Lungpacer DPTS (plus standard of care) as compared to Control (standard of care only) in patients aged 18 years or older who are receiving mechanical ventilation. Eligible Subjects will have received mechanical ventilation for ≥96 hours (4 days) and have failed two weaning attempts.
The goal or outcome is to show a numerically greater proportion of subjects weaned in the Treatment (Lungpacer DPTS) group as compared to the Control group.
The intended patient population is applicable for Lungpacer Diaphragm Pacing Therapy (DPT) because there are no noninvasive alternative treatments for patients who are difficult to wean from MV (i.e., ≥96 hours (4 days) on MV) or who have required prolonged MV (>7 days). The intended patient population includes approximately one-third of all patients on mechanical ventilation. Under standard of care, approximately 50% of these patients will recover from mechanical ventilation (Jung, 2016). Standard of care involves daily weaning attempts, known as Spontaneous Breathing Trials (SBTs) or Ventilator Liberation Trials (VLTs) that are intended to encourage diaphragm use and strengthening over time.Therefore, Lungpacer DPT efficacy evaluation must be compared to standard of care in a Control group. Lack of recovery from mechanical ventilation may be due to the inability of a patient to participate in VLTs or weaning attempts, due to extensive diaphragm weakness or sedation, the inability of VLTs to induce sufficient diaphragm strengthening, or co-morbidities that prevent recovery.
The criteria were revised on the registry on Nov 12, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subject receives Lungpacer Catheter for transvenous phrenic nerve stimulation to deliver Diaphragm Pacing Therapy Sessions. DPT sessions are 6 sets of 10, delivered twice daily, for a total of 120 stimulation reps per day, plus standard of care for weaning from mechanical ventilation.
Device: Lungpacer Diaphragm Pacing Therapy
Subject does not receive Lungpacer Catheter or DPT. Subject receives only Standard of care for weaning from mechanical ventilation.
Transvenous phrenic nerve stimulation to induce diaphragm contraction.
Also known as: Lungpacer DPTS, AeroPace System
Successful Weaning
Cumulative percentage of subjects successfully weaned by Day 30.
Time frame: Through Day 30
Adverse Event Profile
Characterize the adverse event profile to support an observed consistent risk profile for subjects randomized to Treatment compared to subjects randomized to Control. Percentage of subjects with adverse events (AE) and serious adverse events (SAE) were summarized for the Treatment group and the Control group by system organ class (SOC) and lower level term. No formal statistical hypothesis test or criterion for the primary safety endpoint was defined.
Time frame: 30 days
Days on Mechanical Ventilation (MV)
The average days on mechanical ventilation from Day 1 to removal from MV associated with successful weaning or Day 30, whichever comes first, will be statistically significantly smaller for subjects randomized to Treatment as compared to subjects randomized to Control.
Time frame: Successful weaning or Day 30
Maximal Inspiratory Pressure (MIP) Change
The mean improvement in inspiratory muscle strength as shown by the change in Maximal Inspiratory Pressure (MIP) from randomization to last available measure in subjects randomized to Treatment is superior to that in subjects randomized to Control.
Time frame: Baseline last available measure through Day 30.
Rapid Shallow Breathing Index (RSBI) Change
To determine change in Rapid Shallow Breathing Index (RSBI) from randomization to last available measure in subjects randomized to Treatment as compared to Control. RSBI measures the ratio of the respiratory rate to Tidal Volume in breaths/min/L and is commonly used as an index for weaning success. A reduction in RSBI is considered as clinical improvement.
Time frame: Baseline to last available measure through Day 30.
Survival
Cumulative percentage of subjects who survived through Day 30.
Time frame: 30 days
Re-instatements of MV (After Successful Weaning) Through Day 30.
Assessment of re-instatements of MV in subjects who were successful weaned through Day 30 in the Treatment group as compared to the Control group.
Time frame: Through Day 30.
Tracheotomy After Randomization
Assessment of percentage of subjects after randomization to Day 30 that required tracheostomy in the Treatment group as compared to the Control group.
Time frame: Through 30 days
ICU Discharges to Day 30.
Assessment of ICU discharges to Day 30 in the Treatment group as compared to the Control group.
Time frame: through 30 days
Hospital Discharges to Day 30.
Assessment of hospital admissions and discharges to Day 30 in the Treatment group as compared to the Control group.
Time frame: through 30 days
Adaptive from N=200 to N=400 randomized subjects based on a Bayesian group sequential design.
| Milestone | Treatment | Control |
|---|---|---|
| Started | 109 | 114 |
| Completed | 102 | 114 |
| Not completed | 7 | 0 |
| Withdrew: Treatment catheter unable to be placed successfully in 7 subjects. | 7 | 0 |
Cumulative percentage of subjects successfully weaned by Day 30.
| Cumulative percentage of subjects | Treatment | Control |
|---|---|---|
| Successful Weaning | 74.2 (66.5 to 80.9) | 63.7 (55.8 to 70.9) |
Characterize the adverse event profile to support an observed consistent risk profile for subjects randomized to Treatment compared to subjects randomized to Control. Percentage of subjects with adverse events (AE) and serious adverse events (SAE) were summarized for the Treatment group and the Control group by system organ class (SOC) and lower level term. No formal statistical hypothesis test or criterion for the primary safety endpoint was defined.
| Percentage of subjects | Treatment | Control |
|---|---|---|
| Adverse Event Profile | 67.9 | 52.6 |
The average days on mechanical ventilation from Day 1 to removal from MV associated with successful weaning or Day 30, whichever comes first, will be statistically significantly smaller for subjects randomized to Treatment as compared to subjects randomized to Control.
| days | Treatment | Control |
|---|---|---|
| Days on Mechanical Ventilation (MV) | 14.57 ± 0.936 | 17.03 ± 0.881 |
The mean improvement in inspiratory muscle strength as shown by the change in Maximal Inspiratory Pressure (MIP) from randomization to last available measure in subjects randomized to Treatment is superior to that in subjects randomized to Control.
| cm H2O | Treatment | Control |
|---|---|---|
| Maximal Inspiratory Pressure (MIP) Change | 13.9 ± 19.3 | 14.9 ± 19.9 |
To determine change in Rapid Shallow Breathing Index (RSBI) from randomization to last available measure in subjects randomized to Treatment as compared to Control. RSBI measures the ratio of the respiratory rate to Tidal Volume in breaths/min/L and is commonly used as an index for weaning success. A reduction in RSBI is considered as clinical improvement.
| breaths/min/L | Treatment | Control |
|---|---|---|
| Rapid Shallow Breathing Index (RSBI) Change | -35.0 ± 107.9 | -19.8 ± 78.2 |
Cumulative percentage of subjects who survived through Day 30.
| Cumulative percentage of subjects | Treatment | Control |
|---|---|---|
| Survival | 90.9 (85.4 to 94.9) | 87.9 (82.3 to 92.3) |
Assessment of re-instatements of MV in subjects who were successful weaned through Day 30 in the Treatment group as compared to the Control group.
| % of subjects reinstated to MV | Treatment | Control |
|---|---|---|
| Re-instatements of MV (After Successful Weaning) Through Day 30. | 5.6 | 14.5 |
Assessment of percentage of subjects after randomization to Day 30 that required tracheostomy in the Treatment group as compared to the Control group.
| percentage of subjects | Treatment | Control |
|---|---|---|
| Tracheotomy After Randomization | 12.8 | 18.9 |
Assessment of ICU discharges to Day 30 in the Treatment group as compared to the Control group.
| percentage of subjects | Treatment | Control |
|---|---|---|
| ICU Discharges to Day 30. | 54.5 | 50.9 |
Assessment of hospital admissions and discharges to Day 30 in the Treatment group as compared to the Control group.
| percentage of subjects | Treatment | Control |
|---|---|---|
| Hospital Discharges to Day 30. | 38.6 | 33.0 |
Collected over AEs and SAEs were collected in RESCUE 3 from enrollment through Day 30/32 unless the subject was withdrawn from the study or died. Treatment subjects with an unsuccessful Catheter placement were followed for 48 hours after the procedure and then exited from the study. Treatment subjects who did not wean by Day 30, had their Catheter removed on Day 30 and were then followed for 48 hours (Day 32) for safety events and then exited from the study.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment | 10/109 (9.2%) | 39/109 (35.8%) | 0/109 (0%) |
| Control | 12/114 (10.5%) | 27/114 (23.7%) | 0/114 (0%) |
| Event | Treatment | Control |
|---|---|---|
| Ventilator-associated pneumoniaInfections and infestations | 7/109 | 1/114 |
| PneumoniaInfections and infestations | 2/109 | 4/114 |
| SepsisInfections and infestations | 3/109 | 0/114 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 3/109 | 0/114 |
| Septic shockInfections and infestations | 2/109 | 3/114 |
| Respiratory insufficiencyRespiratory, thoracic and mediastinal disorders | 0/109 | 3/114 |
| Cardiac arrestCardiac disorders | 2/109 | 2/114 |
| Cardiopulmonary arrestCardiac disorders | 2/109 | 0/114 |
| Pulseless electrical activityCardiac disorders | 2/109 | 0/114 |
| BacteremiaInfections and infestations | 2/109 | 1/114 |
| Age, Continuous(Years) | Treatment | Control | Total |
|---|---|---|---|
| Mean | 64.9 ± 12 | 63.8 ± 11.5 | 64.4 ± 11.8 |
| Sex: Female, Male(Participants) | Treatment | Control | Total |
|---|---|---|---|
| Female | 38 | 38 | 76 |
| Male | 71 | 76 | 147 |
| Ethnicity (NIH/OMB)(Participants) | Treatment | Control | Total |
|---|---|---|---|
| Hispanic or Latino | 6 | 4 | 10 |
| Not Hispanic or Latino | 41 | 44 | 85 |
| Unknown or Not Reported | 62 | 66 | 128 |
| Race (NIH/OMB)(Participants) | Treatment | Control | Total |
|---|---|---|---|
| American Indian or Alaska Native | 2 | 1 | 3 |
| Asian | 3 | 3 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 10 | 7 | 17 |
| White | 35 | 42 | 77 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 59 | 61 | 120 |
| Days on mechanical ventilation at randomization(days) | Treatment | Control | Total |
|---|---|---|---|
| Mean | 27.9 ± 19.0 | 30.3 ± 19.5 | 29.1 ± 19.3 |
| Maximal Inspiratory Pressure (MIP)(cm H2O) | Treatment | Control | Total |
|---|---|---|---|
| Mean | 29.0 ± 11.2 | 28.7 ± 11.0 | 28.8 ± 11.1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Only investigators participating in this clinical trial will be able to see final de-identified participant data at the completion of the study.
Ran from Jun 2019 to primary completion in Dec 2022, 42 months.
Results were first posted in Nov 2026, 3 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ventilator-Induced Lung Injury →
Lungpacer Medical Inc.